P&T Motion History
Statins

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
Individual Statins atorvastatin fluvastatin fluvastatin ER lovastatin lovastatin ER pitavastatin pravastatin rosuvastatin simvastatin	After considering the evidence of safety, efficacy and special populations, I move that the following statins are safe and efficacious: pitavastatin, atorvastatin, fluvastatin, fluvastatin ER, lovastatin, lovastatin ER, pravastatin, rosuvastatin, and simvastatin (all forms) and can be subjected to therapeutic interchange in the Washington Preferred Drug List. The PDL must include at least atorvastatin, rosuvastatin, and pravastatin as preferred agents. I move to not include the combination products as part of the statin drug class on the PDL. Motion: Barkett 2nd: Davydow	February 28, 2024	N/A	N/A	Passed unanimous
Individual Statins atorvastatin fluvastatin fluvastatin ER lovastatin lovastatin ER pitavastatin pravastatin rosuvastatin simvastatin	After considering the evidence of safety, efficacy and special populations, I move that the following statins are safe and efficacious: pitavastatin, atorvastatin, fluvastatin, fluvastatin ER, lovastatin, lovastatin ER, pravastatin, rosuvastatin, and simvastatin (all forms) and can be subjected to therapeutic interchange in the Washington Preferred Drug List. The PDL must include at least one high potency option (atorvastatin and/or rosuvastatin) and the PDL must include pravastatin as an alternative with minimal cytochrome P450	April 18, 2018	Yes Brown Sanderson	Figueroa Storhaug	Passed unanimous

Bold = new this update
Grey = not reviewed, not eligible to be preferred on PDL
*= product is discontinued
3/11/2024

Combination Products atorvastatin/ ezetimibe* lovastatin/ niacin ER simvastatin/ ezetimibe simvastatin/ niacin ER	drug interactions. I move to not include the combination products as part of the statin drug class on the PDL. Motion: Chew 2nd: Johnson				

Bold = new this update
Grey = not reviewed, not eligible to be preferred on PDL
*= product is discontinued
3/11/2024